High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction
MAS9 inhibits CLEC-2-mediated aggregation, platelet spreading and signalling, showing selectivity of CLEC-2 inhibition over GPVI. This study paves the way for future preclinical assays to test the potential of MAS9 as a novel therapeutic tool to treat pathologies such as thromboinflammation and cancer.
Authors
- Alice Y. Pollitt (ORCID: https://orcid.org/0000-0001-8706-5154)
- Johannes A. Eble (ORCID: https://orcid.org/0000-0001-9156-2137)
- Yan Wu (ORCID: https://orcid.org/0000-0002-0470-4908)
- Helma van den Hurk (ORCID: https://orcid.org/0000-0003-0158-4717)
- Ying Di (ORCID: https://orcid.org/0000-0003-1963-0961)
- Jan van Groningen
- Jonathan M. Gibbins (ORCID: https://orcid.org/0000-0002-0372-5352)
- Marcin A. Sowa (ORCID: https://orcid.org/0000-0003-0038-0122)
- Ángel Galindo García (ORCID: https://orcid.org/0000-0003-1176-5917)
Institutions
- Universidade de Santiago de Compostela (ES)
- University of Münster (DE)
- Center for Research in Molecular Medicine and Chronic Diseases (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- University of Reading (GB)
- University of Birmingham (GB)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1111/bph.70036
- Primary Topic
- Lymphatic System and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministerio de Ciencia, Innovación y Universidades
- Academy of Medical Sciences
- European Commission
- Deutsche Forschungsgemeinschaft
- National Centre for the Replacement Refinement and Reduction of Animals in Research
- Horizon 2020 Framework Programme
- H2020 Marie Skłodowska-Curie Actions